Acute pancreatitis

Current Opinion in Gastroenterology

Volumn 13, Issue 5, 1997, Pages 381-385

  Grendell, James H ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYTOKINE; PANCREAS ENZYME; TRYPSIN; TRYPSIN INHIBITOR;

ACUTE PANCREATITIS; ANTIBIOTIC THERAPY; COST BENEFIT ANALYSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC SURGERY; ENZYME BLOOD LEVEL; GENE MUTATION; GENETIC DISORDER; HUMAN; NECROSIS; PANCREAS ABSCESS; PANCREAS PSEUDOCYST; PANCREATITIS; PATHOPHYSIOLOGY; PATIENT SELECTION; PROGNOSIS; SHORT SURVEY; SURGICAL DRAINAGE; TREATMENT OUTCOME;

EID: 0030762940     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001574-199709000-00003     Document Type: Short Survey

References (29)

1. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MU, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, et al.: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996, 14:141-145. A single point mutation involving the cationic trypsinogen gene is the cause of hereditary pancreatitis in some kindreds.
2. Cavallini G, Tittobello A, Frulloni G, Masci E, Mariana A, DiFranceso V: Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography. N Engl J Med 1996, 335:919-923. Treatment with gabexate, a trypsin inhibitor, prior to ERCP substantially reduced the frequency of ERCP-related acute pancreatitis.
3. Buchler M, Malfertheiner P, Uhl W, Scholmerich J, Stockmann F, Adler G, Gaus W, Rolle K, Beger HG, and the German Pancreatitis Study Group: Gabexate mesilate in human acute pancreatitis. Gastroenterology 1993, 104:1165-1170.
4. Niederau C, Liddle RA, Ferrell LD, Grendell JH: Beneficial effects of cholecystokinin-receptor blockage and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice: evidence for cholecystokinin as a major factor in the development of acute pancreatitis. J Clin Invest 1986, 78:1056-1063.
5. McKay CJ, Gallagher G, Brooks B, Imrie CW, Baxter JN: Increased monocyte cytokine production in association with systemic complications in acute pancreatitis. Br J Surg 1996, 83:919-923. Systemic complications in patients with acute pancreatitis were associated with increased in vitro secretion by monocytes of the cytokines tumor necrosis factor-α, interleukin-6 and -8. This suggests a potential benefit for cytokine inhibitors in reducing the frequency of multiorgan system failure in acute pancreatitis.
6. Kingsnorth AN: Early treatment with lexipafant, a platelet-activating factor antagonist, reduces mortality in acute pancreatitis: a double-blind randomized, placebo-controlled study [abstract]. Gastroenterology 1997, 112:A453.
7. Sternby B, O'Brien JF, Zinsmeister AR, DiMagno EP: What is the best biochemical test to diagnose acute pancreatitis? A prospective clinical study. Mayo Clin Proc 1996, 71:1138-1144. Biochemical measurement in blood of a variety of pancreatic enzymes was evaluated in the diagnosis of acute pancreatitis, and measurement of pancreatic isoamylase was recommended as the best choice.
8. Ansari E, Talenti DA, Scopelliti JA, Saadat JM, Zehr BD: Serum lipase and amylase ratio in acute alcoholic and nonalcoholic pancreatitis by using Dupont ACA discrete clinical analyzer. Dig Dis Sci 1996, 41:1823-1827. The lipase:amylase ratio did not help differentiate between alcoholic and nonalcoholic pancreatitis. An amylase level higher than 2000 IU/dL was very specific for nonalcoholic pancreatitis but not sensitive.
9. Stimac D, Rubinic M, Lenac T, Kovac D, Vcev A, Miletic D: Biochemical parameters in the early differentiation of the etiology of acute pancreatitis. Am J Gastroenterol 1996, 91:2355-2359. A multivariate analysis suggested that nonalcoholic and alcoholic pancreatitis can be differentiated using a combination of the lipase:amylase ratio, erythrocyte mean corpuscular volume, and serum alkaline phosphatase.
10. Banks PA, Carr-Locke D, Slivka A, Van Dam J, Lichtenstein DR, Hughes M: Urinary trypsinogen activation peptides (TAP) are not increased in mild ERCP-induced pancreatitis. Pancreas 1996, 12:294-297. Measurement of urinary trypsinogen activation peptide was not helpful in the early diagnosis of ERCP-related pancreatitis.
11. Uhl W, Isenmann R, Curti G, Vogel R, Beger HG, Buchler MW: Influence of etiology on the course and outcome of acute pancreatitis. Pancreas 1996, 13:335-343. No statistically significant differences were observed in the rate of infected necrosis or mortality among alcohol-related acute pancreatitis, gallstone acute pancreatitis, and acute pancreatitis due to other causes. However, there was a trend toward higher mortality in gallstone pancreatitis.
12. Kemppainen E, Sand J, Puolakkanen P, Laine S, Hedstrom J, Sainio V, Haapianen R, Nordback F: Pancreatitis associated protein as an early marker of acute pancreatitis. Gut 1996, 39:675-678. Admission values for pancreatitis associated protein are no better than those for C-reactive protein in distinguishing severe from mild acute pancreatitis.
13. Kemppainen E, Sainio V, Haapianen R, Kivisaari L, Kivilaakso E, Puolakkainen P: Early localization of necrosis by contrast-enhanced computed tomography can predict outcome in severe acute pancreatitis. Br J Surg 1996, 83:924-929. In this report the presence on CT of necrosis in the head of the pancreas was a stronger predictor of complications than the extent of involvement of the gland as estimated by CT.
14. Foitzik T, Bassi DG, Schmidt J, Lewandrowki BK, Fernandez-del Castillo C, Rattner DW, Warshaw AL: Intravenous contrast medium accentuates the severity of acute necrotizing pancreatitis in the rat Gastroenterology 1994, 106:207-214.
15. McMenamin DA, Gates LK Jr: A retrospective analysis of the effect of contrast-enhanced CT on the outcome of acute pancreatitis. Am J Gastroenterol 1996, 91:1384-1387. Patients who had undergone early contrast-enhanced CT had longer hospitalizations than those who did not.
16. Ljutic D, Piplovic-Vukovic T, Raos V, Andrews P: Acute renal failure as a complication of acute pancreatitis. Ren Fail 1996, 18:629-633. In this series acute renal failure occurred in only 4.4% of patients with acute pancreatitis but was associated with a mortality of 58%.
17. Kes P, Vucicevic Z, Ratkovic-Gusic I, Fotivec A: Acute renal failure complicating severe acute pancreatitis. Ren Fail 1996, 18:621-628. Acute renal failure was observed in 14% of patients, usually as part of multiorgan system failure, and was associated with a mortality of 75%.
18. Heresbach D, Devillers A, Rabot A, Moisan A, Malledant Y, Bourget P, Bretagne JF, Gosselin M: Labeled granulocyte scanning for the diagnosis of infected necrosis in acute pancreatitis: what kind of labeling should be used? Pancreas 1996, 12:381-387. Scintigraphy using labeled granulocytes can aid in the identification of infected necrosis, but it does not appear preferable in most cases to CT-guided aspiration of suspected areas of infected necrosis.
19. Benney T, Belli D, Bugmann P, Bechetti M, Morel P, Le Coultre C: Influence of severe underlying pathology and hypovolemic shock on the development of acute pancreatitis in children. J Pediatr Surg 1996, 34:1256-1266. Not surprisingly acute pancreatitis in children carries a higher mortality if it develops in the setting of hypovolemic shock or other comorbid conditions.
20. Folsch UR, Nitsche R, Ludtke R, Hilgers RA, Creutzfeldt W: Early ERCP and papillotomy compared with conservative treatment for acute biliary pancreatitis. The German Study Group on Acute Biliary Pancreatitis. N Engl J Med 1997, 336:237-242. In a highly selected group of patients with gallstone pancreatitis but without evidence of cholangitis or biliary obstruction, early ERCP and sphincterotomy did not improve the outcome.
21. Neoptolemos JP, Carr-Locke DL, London NJ, Bailey IA, James D, Fossard DP: Controlled trial of urgent endoscopic retrograde cholangiopancreatography and endoscopic sphincterotomy versus conservative treatment for acute pancreatitis due to gallstones. Lancet 1988, ii:979-983.
22. Nowak A, Nowakowska-Dulawa E, Marek TA, Rybicka J: Final results of the prospective, randomized, controlled study for endoscopic sphincterotomy versus conventional management in acute biliary pancreatitis [abstract]. Gastroenterology 1995, 108:A380.
23. Farkas G, Marton J, Mandi Y, Szederrenyi E: Surgical strategy and management of infected pancreatic necrosis. Br J Surg 1996, 83:930-933. Operative debridement with continuous lavage and drainage along with antimicrobial therapy produced outstanding results with a hospital mortality of only 7%.
24. Baron TH, Thaggard WG, Morgan DE, Stanley RJ: Endoscopic therapy for organized pancreatic necrosis. Gastroenterology 1996, 111:755-764. Three patients with infected pancreatic necrosis were treated successfully using endoscopic therapy.
25. Dubner H, Steinberg WH, Hill M, Bassi C, Chardavoyne R, Bank S: Infected pancreatic necrosis and peripancreatic fluid collections: serendipitous response to antibiotic and medical therapy in three patients. Pancreas 1996, 12:298-302. Another three patients with infected necrosis survived following antibiotic therapy alone.
26. Uomo G, Visconti M, Manes G, Cause F, Laccetti M, Rabitti PG: Nonsurgical treatment of acute necrotizing pancreatitis. Pancreas 1996, 12:142-148. More evidence that patients with severe acute pancreatitis and sterile necrosis should generally be treated nonoperatively.
27. Barie PS: A critical review of antibiotic prophylaxis in severe acute pancreatitis. Am J Surg 1996, 172(6A):38S-43S. A thorough, scholarly review of this still controversial topic.
28. Behrman SW, Melvin WS, Ellison CS: Pancreatic pseudocysts following acute pancreatitis. Am J Surg 1996, 172:228-231. This small, retrospective review suggests that pseudocysts of 10 cm or more in diameter developing after acute pancreatitis are associated with high rates of morbidity and mortality.
29. Gregor JC, Ponich TP, Detsky AS: Should ERCP be routine after an episode of "idiopathic" pancreatitis? A cost-utility analysis. Gastrointest Endosc 1996, 44:118-123. Based on a mathematical model, the benefit and cost-effectiveness of ERCP would be substantial if a subgroup of these patients with a high likelihood of occult gallstone disease could be identified.